SapC-DOPS Nanovesicles Targeting Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate for effectively targeting and eliminating solid tumors, including brain and gastrointestinal cancers, due to limitations in inducing apoptosis and necrosis in tumor cells.
Innovation Solution
Compositions comprising saposin C (SapC) and dioleoyl phosphatidylserine (DOPS) are developed, which form nanovesicles that induce apoptosis and necrosis in tumor cells by elevating ceramide levels, activated through specific enzymatic pathways, and are administered in various formulations to enhance stability and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then general cancer therapy is provided, but effectiveness in targeting and eliminating solid tumors is inadequate
Solution Approach 1:
The patent applies local quality by modifying the lipid composition of nanovesicles to specifically recognize phosphatidylserine exposed on tumor cell membranes. The SapC-DOPS nanovesicles are engineered with dioleoyl phosphatidylserine that binds to phosphatidylserine-rich membranes, creating a localized targeting mechanism that distinguishes tumor cells from healthy cells based on their membrane composition differences.
Solution Approach 2:
The patent employs parameter changes by altering the chemical composition parameters of the therapeutic agent - specifically incorporating saposin C and dioleoyl phosphatidylserine in specific molar ratios (1:4 to 1:20). These compositional parameter changes enable the nanovesicles to induce apoptosis through ceramide elevation, providing a new mechanism of action that overcomes limitations of conventional treatments.
2Reliability
If SapC-DOPS nanovesicles are administered, then apoptosis and necrosis are induced in tumor cells, but formulation stability and delivery efficiency must be optimized
Solution Approach 1:
The patent applies composite materials by combining saposin C (a glycoprotein) with dioleoyl phosphatidylserine (a phospholipid) to create SapC-DOPS nanovesicles. This composite formulation leverages the membrane-disrupting properties of SapC and the target-specific binding of DOPS to phosphatidylserine, creating a synergistic therapeutic agent that achieves both stability and effective tumor cell targeting.
Solution Approach 2:
The patent uses phosphatidylserine as an intermediary that mediates between the SapC-DOPS nanovesicles and tumor cell membranes. The phosphatidylserine component acts as a bridge, binding to phosphatidylserine exposed on the surface of apoptotic and necrotic tumor cells, thereby facilitating selective delivery and activation of the therapeutic effect while maintaining formulation stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SapC-DOPS compositions demonstrate efficacy in treating a wide range of tumor types by inducing apoptosis and necrosis, showing promise in clinical trials with minimal adverse events, particularly in glioma, ependymoma, and rectal adenocarcinoma, with sustained treatment outcomes.
Implementation Method 1
Nanovesicles comprising saposin C ('SapC') and dioleoyl phosphatidylserine (DOPS) have high affinity for phosphatidylserine-rich membranes in vitro and in vivo
Implementation Method 2
The proposed mechanism by which the SapC-DOPS nanovesicles induce apoptosis is via ceramide elevation through activation of β-glucosidase and acid sphingomyelinase (with subsequent degradation of glucosylceramide and sphingomyelin, respectively)
Data Source
AI summary
Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.